Results 121 to 130 of about 22,249,811 (294)

Image2_Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework.PNG

, 2022
While anti-PD-1 and anti-PD-L1 [anti-PD-(L)1] monotherapies are effective treatments for many types of cancer, high variability in patient responses is observed in clinical trials.
Jessica C. Leete (14213357), Blerta Shtylla (784483), Michael G. Zager (14213360), Cynthia J. Musante (3168705), Wenlian Qiao (109935)   +4 more
core   +1 more source

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity

BMC Immunology
Abstract Vanishing bile duct syndrome (VBDS) is a serious drug induced liver injury characterized by chronic cholestasis and loss of intrahepatic bile ducts. VBDS has been reported also following checkpoint inhibitor treatment. We compared CD3 + , CD4 + , CD8 + , CD20 + , CD57 + , PD-1 + and PD-L1 + lymphocyte infiltrates in liver biopsies of
Saarela, Miro, Parviainen, Essi, Lleo, Ana, di Tommaso, Luca, Raunio, Hanna, Kankaanranta, Krista, Vuopala, Katri, Rönkä, Aino, Nurmenniemi, Sini, Kallio, Raija, Jukkola, Arja, Selander, Katri S.   +11 more
openaire   +5 more sources

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

Molecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski, Liudmyla Dolinchuk, Michał Jerzak, Albert Gandurski, Tomasz Grochowski, Weronika Wojtyś, Maciej Zadrożny, Wojciech Kaźmierczak, Małgorzata Lenarcik, Marta Matejak‐Górska, Radosław Samsel, Tomasz Olesiński, Dawid Walerych   +12 more
wiley   +1 more source

DataSheet2_Sources of inter-individual variability leading to significant changes in anti-PD-1 and anti-PD-L1 efficacy identified in mouse tumor models using a QSP framework.xlsx

, 2022
While anti-PD-1 and anti-PD-L1 [anti-PD-(L)1] monotherapies are effective treatments for many types of cancer, high variability in patient responses is observed in clinical trials.
Jessica C. Leete (14213357), Blerta Shtylla (784483), Michael G. Zager (14213360), Cynthia J. Musante (3168705), Wenlian Qiao (109935)   +4 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Nachweis der Immuncheckpoint-Komponenten PD-L1 und PD-1 in Tumor- und Immunzellen bei Patienten mit Nierentumoren

Die Immun-Checkpoint-Inhibition blockiert die ko-inhibitorische Interaktion zwischen Lymphozyten und Tumorzellen in der Tumormikroumgebung und stellt eine essentielle Therapieoption für metastasierte Krebserkrankungen, einschließlich Nierentumoren dar ...
Schultz, Carolin
core   +1 more source

Polarization‐resolved femtosecond Vis/IR spectroscopy tailored for resolving weak signals in biological samples using minimal sample volume

FEBS Open Bio, EarlyView.
Unique biological samples, such as site‐specific mutant proteins, are available only in limited quantities. Here, we present a polarization‐resolved transient infrared spectroscopy setup with referencing to improve signal‐to‐noise tailored towards tracing small signals. We provide an overview of characterizing the excitation conditions for polarization‐
Clark Zahn, Karsten Heyne
wiley   +1 more source

Visita Prof. PD Lyden a Roma

, 2008
PD Lyden è professore di neurologia alla UCSD dove dirige lo Stroke Center. E' un esperto di fama internazionale di terapia dell'ictus acuto. Durante il soggiorno a Roma ha partecipato alla pianificazione di attività comuni di ricerca, ha collaborato ...
Lyden PD, FIORELLI, Marco
core  

C2α‐carbanion‐protonating glutamate discloses tradeoffs between substrate accommodation and reaction rate in actinobacterial 2‐hydroxyacyl‐CoA lyase

FEBS Open Bio, EarlyView.
Enzymes of the 2‐hydroxyacyl‐CoA lyase group catalyze the condensation of formyl‐CoA with aldehydes or ketones. Thus, by structural adaptation of active sites, practically any pharmaceutically and industrially important 2‐hydroxyacid could be biotechnologically synthesized. Combining crystal structure analysis, active site mutations and kinetic assays,
Michael Zahn, Barbara Seroka, Ryszard Lazny, Zenon Lotowski, Thore Rohwerder   +4 more
wiley   +1 more source

PD-1 and PD-L1 expression and tissue distribution in LN tissues.

, 2019
Representative examples of PD-1 (A, C and E) or PD-L1 (B, D and F) immunohistochemistry staining of LNs of reactive HIV-uninfected (#177-1I, A-B), viremic (#177-1E, C-D) and aviremic ART treated HIV-infected individual (#092–2, E-F).
Riddhima Banga (634344), Alessandra Noto (7022864), Craig Fenwick (1792990), Olivia Munoz (7022867), Laurence de Leval (135768), Matthias Cavassini (146654), Jean-Marc Corpataux (798979), Francesco Andrea Procopio (7022861), Giuseppe Pantaleo (10464), Matthieu Perreau (268148), Kalliopi Ioannidou (186497), Caterina Rebecchini (7022858), Khalid Ohmiti (430647)   +12 more
core   +1 more source